Centogene (NASDAQ:CNTG) is set to issue its quarterly earnings data before the market opens on Thursday, December 5th.
Shares of CNTG traded down $0.09 during mid-day trading on Tuesday, hitting $12.16. 3,704 shares of the company traded hands, compared to its average volume of 102,211. Centogene has a one year low of $11.81 and a one year high of $15.59.
Several research analysts have issued reports on the company. Evercore ISI assumed coverage on Centogene in a report on Monday. They set an “outperform” rating and a $17.00 price objective on the stock. Robert W. Baird started coverage on Centogene in a research report on Tuesday. They issued an “outperform” rating and a $15.00 price objective on the stock. Finally, BTIG Research began coverage on Centogene in a research note on Monday. They issued a “buy” rating and a $18.00 target price for the company.
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
Further Reading: What is a trade deficit?
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.